JP2022081988A - Wholly plastic nasal cavity preparation administration device - Google Patents

Abstract

To provide a nasal cavity preparation administration device which is wholly made from plastic, has a simplified structure, functionality, and operability to prevent erroneous operation, has improved usability, achieves stable preparation administration to a nasal cavity, has improved disposability, and enables cost down.SOLUTION: A wholly plastic nasal cavity preparation administration device includes: a capsule mounting part; a pressing pump part inside which air is stored to send the air to the capsule mounting part and which is made to communicate with the capsule mounting part; a preparation jet nozzle part which is made to be mountable on the capsule mounting part and communicate with the capsule mounting part and which is to be inserted into a nasal cavity; a first acute angle projection for punching a lower part of a capsule, the first projection provided on the capsule mounting part; and a second acute angle projection for punching an upper part of the capsule, the second projection provided on the preparation jet nozzle part.SELECTED DRAWING: Figure 1

Description

The present invention relates to an intranasal preparation administration device used for intranasal administration of a powdered preparation encapsulated in a capsule, and particularly to an all-plastic intranasal preparation administration device in which all members are made of plastic.

Conventionally, as an intranasal formulation administration device, a type of nasal cavity in which a capsule filled with a powder formulation is set inside the intranasal formulation administration device and the capsule is perforated and the needle is inserted into the capsule for administration. There is an internal formulation administration device. In this type, metal hollow needles are the mainstream, and metal hollow needles secure air and drug flow holes. Further, for example, there is one described in Patent Document 1, but if a hollow needle as described in Patent Document 1 is made of plastic, there is a problem in strength.

In addition, as an intranasal formulation administration device, a capsule filled with a powder formulation is set inside the intranasal formulation administration device, a through hole is made in the capsule with a pin of a drilling tool, and then the pin is returned to the original position for administration. There is also a type of intranasal preparation administration device that performs the above. As a device for administering an intranasal pharmaceutical product of this type, for example, there is one described in Patent Document 2.

The intranasal pharmaceutical product administration devices described in Patent Documents 1 and 2 described above have complicated structures, functions, and operability, and there is room for improvement. In addition, a device for administering an intranasal pharmaceutical product having such a complicated structure, function, and operability has been generally used in the past.

All conventional intranasal pharmaceutical administration devices have been composed of different materials such as plastic and metal. In such a structure composed of different materials such as plastic and metal, there is a problem in the disposability of the device. Further, the use of such different materials has a problem that the structure of the device is complicated and the cost is high. In addition, when the needle of the intranasal-formation administration device is made of plastic, if it is elongated and pointed like a needle, it may break strongly. If it breaks in the middle, plastic fragments may be mixed into the formulation, so a structure that does not break has been desired.

Japanese Patent Application Laid-Open No. 8-243164 Japanese Patent Application Laid-Open No. 8-206210

The present invention has been made in view of the above-mentioned problems of the prior art. The entire device is made of plastic, and the structure, function, and operability are simplified to prevent erroneous operation, improve usability, and enter the nasal cavity. It is an object of the present invention to provide an intranasal preparation administration device capable of achieving stable administration of a pharmaceutical product to the patient, improving disposability, and reducing the cost.

In order to solve the above-mentioned problems, the intranasal-formation-administering device of the present invention is an all-plastic intranasal-formally-administering device in which all the members are made of plastic, and a capsule containing a powder-form is placed inside. In order to send air to the capsule mounting portion and the capsule mounting portion, the air is accommodated inside and can be mounted on the capsule mounting portion and the pressing pump portion which is communicated with the capsule mounting portion. The pharmaceutical product ejection nozzle portion to be inserted into the nasal cavity, which is communicated with the capsule mounting portion, and the first sharp angle protrusion for punching into the lower portion of the capsule provided in the capsule mounting portion. It is an all-plastic intranasal pharmaceutical product administration device comprising a second sharp-angled protrusion for piercing the upper part of the capsule provided in the pharmaceutical product ejection nozzle portion.

It is preferable that an air flow path groove for air to flow in the axial direction is formed in each of the first acute-angled protrusion and the second acute-angled protrusion.

The first pyramid is a first pyramidal projection having a first sharp pyramid tip and a first large-diameter pyramid base having a larger angle than the first sharp pyramid tip. A second pyramidal projection having a second sharp pyramid tip and a second large-diameter pyramid base having a larger angle than the second sharp pyramid tip. It is preferable to be.

At least a part of the middle abdomen of the first acute-angled process is provided with a first step portion for making the first sharp-angled process larger in diameter, and at least a part of the middle abdomen of the second acute-angled process is provided. A second step portion for increasing the diameter of the second acute-angled protrusion is provided, and each hole drilled in the upper and lower portions of the capsule is expanded by the first step portion and the second step portion. It is preferable that it is configured as such.

By mounting the capsule on the capsule mounting portion and mounting the pharmaceutical product ejection nozzle portion on the capsule mounting portion, the lower part and the upper part of the capsule are perforated and the pressing pump portion is pressed. It is preferable that the powdered preparation is administered into the nasal cavity from the nozzle portion for ejecting the preparation.

The capsule is placed on the capsule placement portion, and the formulation ejection nozzle portion is attached to the capsule mounting portion to pierce the lower part and the upper part of the capsule, respectively, and the formulation ejection nozzle portion is rotated. Then, the first acute-angled projection and the second acute-angled projection penetrated into the capsule are rotated to ensure more air flow to each of the holes drilled in the upper and lower parts of the capsule. Is preferable.

It is preferable that the capsule mounting portion is detachably attached to the pressing pump portion.

It is preferable that the capsule mounting portion, the pharmaceutical product ejection nozzle portion, the first acute-angled protrusion and the second acute-angled protrusion are made of hard plastic, and the pressing pump part is made of soft plastic. be.

It is preferable that the all-plastic intranasal preparation administration device is disposable.

It is preferable that the all-plastic intranasal preparation administration device is transparent and the inside is visible.

According to the present invention, the entire device is made of plastic to simplify the structure, function, and operability to prevent erroneous operation, improve usability, and provide a stable formulation in the nasal cavity without the risk of plastic contamination. It has a great effect of achieving administration, improving disposability, and reducing costs. Further, according to the present invention, there is also an effect that disposable use is possible by making the entire device plastic.

It is a perspective exploded view which shows one Embodiment of the all-plastic intranasal pharmaceutical agent administration device which concerns on this invention. It is a front view which shows one Embodiment of the all-plastic intranasal pharmaceutical agent administration device which concerns on this invention. FIG. 2 is a cross-sectional view taken along the line AA of FIG. 2, showing a state in which a capsule is not housed. It is a plan view of FIG. It is a top view of the capsule mounting part. FIG. 2 is a cross-sectional view taken along the line AA of FIG. 2, showing a state in which a capsule is housed. It is a perspective view which shows one embodiment of the 1st acute angle process and the 2nd acute angle process of the all-plastic intranasal pharmaceutical product administration device which concerns on this invention. It is a schematic diagram which shows the mode that the capsule is perforated by the first acute angle projection or the second acute angle projection of the all-plastic intranasal pharmaceutical product administration device according to the present invention. It is a schematic diagram explaining the mode of rotating the pharmaceutical product ejection nozzle part in the all-plastic intranasal pharmaceutical product administration device according to the present invention.

Hereinafter, embodiments of the present invention will be described with reference to the accompanying drawings. The same member is indicated by the same reference numeral.

In FIGS. 1 to 3 and 6, reference numeral 10 indicates an embodiment of the all-plastic intranasal pharmaceutical agent administration device (hereinafter, may be simply referred to as “nasal pharmaceutical agent administration device”) according to the present invention. ..

The intranasal-formation-administering device 10 according to the present invention is an all-plastic intranasal-formally-administered device in which all members are made of plastic, and a capsule-mounted capsule 12 in which a powder-form is encapsulated is placed. Since the air is sent to the placement portion 14 and the capsule mounting portion 14, the air is accommodated inside and can be mounted on the pressing pump portion 16 and the capsule mounting portion 14 which are communicated with the capsule mounting portion 14. In order to pierce the pharmaceutical product ejection nozzle 18 inserted into the nasal cavity, which is communicated with the capsule mounting portion 14, and the lower portion 20 of the capsule 12 provided in the capsule mounting portion 14. The administration of an all-plastic intranasal pharmaceutical product comprising the first sharp-angled protrusion 22 and the second sharp-angled protrusion 26 for piercing the upper portion 24 of the capsule provided in the pharmaceutical product ejection nozzle portion 18. It is a device.

The intranasal pharmaceutical product administration device 10 according to the present invention is an administration device that enables administration of a quantitative powder pharmaceutical product into the nasal cavity. It is composed of three members, a capsule mounting portion 14 and a lower pressing pump portion, all of which are molded from plastic.

The pharmaceutical product ejection nozzle portion 18 is provided with an intranasal pharmaceutical product administration tube 30 at the upper end of the dome-shaped base 28, and when the nasal drop is performed, the intranasal pharmaceutical product administration tube 30 is inserted into the nasal cavity. Drop the nose. The capsule storage portion 32 of the capsule mounting portion 14 is provided in parallel with the intranasal preparation administration tube 30, and the lower outer edge portion of the capsule mounting portion 14 has an engaging protrusion rib 34 in the circumferential direction. It is provided. By bringing the capsule mounting portion 14 and the pressing pump portion 16 into contact with each other and rotating one of them, the engaging groove 36 and the engaging protrusion rib 34 formed on the upper outer edge portion of the pressing pump portion 16 are formed. The capsule mounting portion 14 is detachably attached to the pressing pump portion 16 so as to be engaged, and the pressing pump portion 16 and the capsule mounting portion 14 are integrated. The inner diameter of the capsule housing portion 32 and the inner diameter of the intranasal pharmaceutical administration cylinder 30 are set to have a diameter close to the outer diameter of the capsule in which the powder pharmaceutical product is encapsulated.

The second acute-angled protrusion 26 is provided inside the intranasal pharmaceutical-administered cylinder 30 of the pharmaceutical product ejection nozzle portion 18 so as to face downward, and a plurality of distribution holes are provided around the base of the second acute-angled protrusion 26. 38 (three in the illustrated example) are formed (see FIGS. 3, 4, 6 and the like). More specifically, the nasal cavity preparation administration tube 30 is provided with a flat plate that crosses the tubular radial direction at an arbitrary height, and the flat plate is provided with a plurality of through holes and a second acute-angled protrusion 26.

A plurality of engaging ribs 40 are provided in the axial direction on the outer peripheral surface of the capsule mounting portion 14, and the inner peripheral surface of the dome-shaped base 28 of the pharmaceutical product ejection nozzle portion 18 is the capsule mounting portion 14. By engaging with the outer peripheral surface, the pharmaceutical product ejection nozzle portion 18 is mounted on the capsule mounting portion 14.

The first acute-angled protrusion 22 is provided inside the capsule storage portion 32 of the capsule mounting portion 14 so as to face upward, and a plurality of openings flow around the base of the first acute-angled protrusion 22. Holes 42 (three in the illustrated example) are formed (see FIGS. 3, 5, 6 and the like). In the illustrated example, the opening flow hole 42 around the base of the first acute-angled protrusion 22 is formed slightly larger than the plurality of flow holes 38 around the base of the second acute-angled protrusion 26. .. More specifically, a flat plate that crosses the tubular radial direction is provided at the bottom of the capsule storage portion 32, and a plurality of through holes and a first acute-angled protrusion 22 are provided on the flat plate in the vicinity of the bottom of the capsule storage portion 32. It is said that.

Further, the structure of the first acute-angled protrusion 22 and the second acute-angled protrusion 26 is shown in FIG. The first acute-angled projection 22 and the second acute-angled projection 26 have basically the same structure, and air flows in each of the first acute-angled projection 22 and the second acute-angled projection 26 in the axial direction. Air flow path grooves 44 are formed at a plurality of places (three in the illustrated example). In the illustrated example, an example is shown in which the air flow path groove 44 for allowing air to flow in the axial direction is provided on the outer peripheral surfaces of each of the first acute-angled protrusion 22 and the second acute-angled protrusion 26. In the illustrated example, the first acute-angled projection 22 and the second acute-angled projection 26 show an example of a solid acute-angled projection. As described above, by forming the first acute-angled protrusion 22 and the second acute-angled protrusion 26 with the air flow path groove, the air and powder preparation passing through the opening flow hole 42 and the flow hole 38 can be obtained from the first acute-angled protrusion 22. It is configured so that it can easily flow around the acute-angled protrusion 22 and the second acute-angled protrusion 26.

Further, as is well shown in FIG. 7, the first acute-angled projection 22 has a first acute-angled pyramid tip 46 and a first large-diameter pyramid base having a larger angle than the acute-angled pyramid tip 46. It is a first pyramidal projection having 48 and. Here, the first-diameter large-angle pyramid base 48 having a larger angle than the first acute-angled pyramid tip 46 has a first diameter than the base angle θ1 of the first acute-angled pyramid tip 46. It means that the base angle θ2 of the large pyramid base 48 is larger.

Further, as is well shown in FIG. 7, the second acute-angled projection 26 has a second acute-angled pyramid tip portion 50 and a second large-diameter pyramid base portion having an angle larger than that of the acute-angled pyramid tip portion 50. It is a second pyramidal projection having 52. Here, the second large-diameter pyramid base 52 having a larger angle than the second acute-angled pyramid tip 50 has a second diameter than the base angle θ1 of the second acute-angled pyramid tip 50. It means that the base angle θ2 of the large pyramid base 52 is larger.

In the illustrated example, the example in which the first acute-angled projection 22 and the second acute-angled projection 26 are triangular pyramidal projections is shown.

Further, in the illustrated embodiment, as is well shown in FIG. 7, the first step portion 54 that causes the first acute-angled projection 22 to have a large diameter at least a part of the middle abdomen of the first acute-angled projection 22. Is provided. Similarly, at least a part of the middle abdomen of the second acute-angled projection 26 is provided with a second step portion 56 for making the second acute-angled projection 26 larger in diameter.

By providing the first step portion 54 and the second step portion 56, as shown in FIG. 8, the holes drilled in the upper and lower portions of the capsule 12 are formed by the step portions 54 and 56, respectively. It is configured to be expanded.

FIG. 8 shows how the capsule 12 is perforated by the first acute-angled protrusion 22 or the second acute-angled protrusion 26. The end face of the upper portion 24 or the lower portion 20 of the capsule 12 is first cracked by the first acute-angled pyramid tip 46 or the second acute-angled pyramid tip 50 to obtain a perforated state P1. Then, when the first acute-angled projection 22 or the second acute-angled projection 26 is further pushed in, the inclined surface further tears the crack, so that the hole expands and the drilled state P2 is obtained. Then, the cracked portion of the capsule 12 that closes the air flow path groove 44 of the first acute-angled protrusion 22 or the second acute-angled protrusion 26 is turned up by the first stepped portion 54 or the second stepped portion 56. Then, it becomes a perforated state P3. In the illustrated example, an example in which a pedestal-shaped step portion is provided as the first step portion 54 or the second step portion 56 is shown.

Unlike metal needles, plastic sharp protrusions are prone to curl on the inner surface of the contact area between the sharp protrusion and the capsule during penetration, and this curl interferes with the air flow path groove provided in the pyramidal plastic sharp protrusion. It may not be possible to ensure stable air and drug distribution. In order to solve this, as shown in the figure, the first step portion 54 or the second step portion 56 having a pedestal shape is provided under the first acute angle protrusion 22 or the second acute angle protrusion 26, and the second step portion 56 is provided. It is preferable to secure the flow path by the effect of further expanding the hole formed by the acute-angled projection 22 of 1 or the acute-angled projection 26 of the second. Then, in the illustrated example, while securing the flow path as described above, the lower pressing pump portion 16 is pressed with a finger, and the air in the pressing pump portion 16 is sent into the perforated capsule 12 above the pump. By entraining the powder-form product in the capsule 12, the powder-form product moves to the upper intranasal-formation administration tube 30, and the powder-form product can be administered into the nasal cavity through the intranasal-formation administration tube 30.

Further, in the illustrated example, the capsule mounting portion 14, the pharmaceutical product ejection nozzle portion 18, the first acute-angled projection 22 and the second acute-angled projection 26 are made of hard plastic, and the pressing pump portion 16 is formed. It is made of soft plastic. Here, the term “hard or soft plastic” refers to the classification of plastics defined in JIS K6900. Since the pressing pump portion 16 is pressed by a finger to send air, the pressing pump portion 16 is preferably made of soft plastic. Further, the all-plastic intranasal preparation administration device 10 according to the embodiment of the present invention is transparent and the inside is visible. If the inside is visible, even if it is translucent, it is included in the transparency of the present invention. More specifically, in the all-plastic intranasal preparation administration device 10, the pressing pump portion 16 is translucent, and the other members are not translucent and transparent. In the illustrated example, the pressing pump portion 16 of the all-plastic intranasal pharmaceutical agent administration device 10 is translucent, and the other members are not translucent and transparent, but the present invention is not limited thereto. Opaque or colored plastic may be used. As the plastic, various known resins, particularly synthetic resins, can be applied. For example, acrylic resin, polystyrene, PET resin, polycarbonate, AS resin, vinyl chloride (soft / hard), polyethylene, polypropylene, polyacetal, ABS resin, phenol resin. , Nylon, polycarbonate, etc. can be applied.

The all-plastic intranasal preparation administration device 10 is a disposable type device that can be discarded after use. It is possible to make it disposable because the cost can be reduced by making the entire device plastic.

In the all-plastic intranasal preparation administration device 10 of the present invention, the capsule 12 is placed on the capsule placement portion 14, and the preparation ejection nozzle portion 18 is attached to the capsule placement portion 14, whereby the capsule 12 is mounted. The lower portion 20 and the upper portion 24 of the above are perforated, and the powder formulation is administered into the nasal cavity from the formulation ejection nozzle portion 18 by pressing the pressing pump portion 16. The patient using the intranasal preparation administration device 10 presses the pressing pump unit 16 and sucks the powdered preparation discharged.

Further, in the all-plastic intranasal pharmaceutical product administration device 10 of the present invention, the capsule 12 is placed on the capsule mounting portion 14, and the pharmaceutical product ejection nozzle portion 18 is attached to the capsule mounting portion 14. When the lower portion 20 and the upper portion 24 of the capsule 12 are perforated and the pharmaceutical product ejection nozzle portion 18 is rotated, the first sharp-angled projection 22 and the second sharp-angled projection penetrated through the capsule 12 are rotated. More air flow to each of the holes drilled in the upper and lower parts of the capsule is ensured. Therefore, a more preferred method of using the intranasal pharmaceutical product administration device 10 is to mount the pharmaceutical product ejection nozzle portion 18 on the capsule mounting portion 14 and then rotate the pharmaceutical agent ejection nozzle portion 18. When the pharmaceutical product ejection nozzle portion 18 is rotated, the angle at which the pharmaceutical product ejection nozzle portion 18 is rotated is not particularly limited, but the angle at which the pharmaceutical product ejection nozzle portion 18 is rotated may be, for example, 1 ° or more, preferably 90 ° or more. 120 ° or more is more preferable. Further, the upper limit of the rotation angle is not particularly limited and may be rotated by 360 ° or more, but for example, 270 ° or less is more preferable.

Hereinafter, as an example, an experimental example of sprayability evaluation of the all-plastic intranasal pharmaceutical agent administration device 10 of the present invention will be described, but the present invention is not limited to the description of the following experimental example.

<Experimental Example 1>
Using the all-plastic intranasal formulation administration device 10 of the present invention, the capsule 12 in which the powder formulation is encapsulated is placed on the capsule mounting portion 14 so that the cap side of the capsule faces upward, and the first acute angle is obtained. By pushing the protrusion 22, the lower portion 20 of the capsule 12 was pierced. Then, the intranasal preparation administration device 10 is tilted 90 degrees, and the preparation ejection nozzle portion 18 is attached to the capsule mounting portion 14 and fitted to the capsule body side, and the second acute-angled projection 26 is pushed in. Then, the upper part 24 of the capsule 12 was perforated. The pressure pump unit 16 was pressed to send air to evaluate the discharge rate of the powder pharmaceutical product from the pharmaceutical product ejection nozzle unit 18. The same experiment was repeated 10 times.

In Experimental Example 1, the average emission rate of the powdered product was as high as 79.3%. It can be seen that in the present invention, the usability was improved and stable administration of the pharmaceutical product into the nasal cavity was achieved.

<Experimental Example 2>
Using the all-plastic intranasal preparation administration device 10 of the present invention, the capsule 12 containing the same commercially available powder preparation as in Experimental Example 1 is placed on the capsule placement portion 14 so that the cap side of the capsule faces upward. The capsule 12 was placed and the lower portion 20 of the capsule 12 was pierced by pushing the first acute-angled protrusion 22. Then, the intranasal preparation administration device 10 is tilted 90 degrees, and the preparation ejection nozzle portion 18 is attached to the capsule mounting portion 14 and fitted to the capsule body side, and the second acute-angled projection 26 is pushed in. The upper part 24 of the capsule 12 was perforated. Then, after rotating the pharmaceutical product ejection nozzle portion 18 by 180 degrees, the pressing pump portion 16 was pressed to send air to evaluate the discharge rate of the powder pharmaceutical product from the pharmaceutical product ejection nozzle portion 18. The same experiment was repeated 10 times.

In Experimental Example 2, the average emission rate of the powdered product was as high as 93.8%. It can be seen that in the present invention, the usability was improved and stable administration of the pharmaceutical product into the nasal cavity was achieved. Then, in Experimental Example 2 in which the pharmaceutical product ejection nozzle portion 18 was rotated, it can be seen that particularly stable pharmaceutical agent administration into the nasal cavity was achieved.

In this way, in the all-plastic intranasal pharmaceutical administration device 10 of the present invention, the entire device is made of plastic to simplify the structure, function, and operability, thereby preventing erroneous operation and improving usability. It is possible to achieve stable administration of the pharmaceutical product into the nasal cavity, improve disposability, and reduce costs.

10: All-plastic intranasal formulation administration device, 12: capsule, 14: capsule placement section, 16: pressing pump section, 18: formulation ejection nozzle section, 20: lower part of capsule, 22: first acute-angled protrusion, 24 : Upper part of capsule, 26: Second acute protrusion, 28: Dome-shaped base: 30: Intranasal pharmaceutical dosage tube, 32: Capsule housing, 34: Engagement protrusion rib, 36: Engagement groove, 38: Flow hole , 40: Engagement rib, 42: Opening flow hole, 44: Air flow path groove, 46: First acute-angled pyramid tip, 48: First large-diameter pyramid base, 50: Second acute-angled pyramid tip 52: Second large-diameter pyramid base, 54: First step, 56: Second step, P1 to P3: Drilled state, θ1, θ2: Bottom angle.

Claims (10)

It is an all-plastic intranasal formulation administration device made of all parts made of plastic.
Capsule placement section where capsules containing powdered products are placed inside,
In order to send air to the capsule mounting portion, an air is contained inside and is communicated with the capsule mounting portion.
A pharmaceutical product ejection nozzle portion to be inserted into the nasal cavity, which is attached to the capsule mounting portion and communicates with the capsule mounting portion,
A first acute-angled protrusion for perforating the lower part of the capsule provided in the capsule mounting portion, and
A second acute-angled protrusion for perforating the upper part of the capsule provided in the pharmaceutical product ejection nozzle portion, and
Has an all-plastic intranasal formulation administration device. The all-plastic intranasal preparation administration device according to claim 1, wherein an air flow path groove for allowing air to flow in the axial direction is formed in each of the first acute-angled projection and the second acute-angled projection. The first pyramid is a first pyramidal projection having a first sharp pyramid tip and a first large-diameter pyramid base having a larger angle than the first sharp pyramid tip. A second pyramidal projection having a second sharp pyramid tip and a second large-diameter pyramid base having a larger angle than the second sharp pyramid tip. The all-plastic intranasal preparation administration device according to claim 1 or 2. At least a part of the middle abdomen of the first acute-angled protrusion is provided with a first step portion for making the first sharp-angled protrusion larger in diameter, and at least a part of the middle abdomen of the second acute-angled protrusion is provided. A second step portion for increasing the diameter of the second acute-angled protrusion is provided, and each hole drilled in the upper and lower portions of the capsule is expanded by the first step portion and the second step portion. The all-plastic intranasal preparation administration device according to any one of claims 1 to 3, which is configured as described above. By mounting the capsule on the capsule mounting portion and mounting the pharmaceutical product ejection nozzle portion on the capsule mounting portion, the lower part and the upper part of the capsule are perforated and the pressing pump portion is pressed. The all-plastic intranasal pharmaceutical product administration device according to any one of claims 1 to 4, wherein the powder pharmaceutical product is administered into the nasal cavity from the pharmaceutical product ejection nozzle portion. The capsule is placed on the capsule mounting portion, and the pharmaceutical product ejection nozzle portion is attached to the capsule mounting portion to pierce the lower part and the upper portion of the capsule, respectively, and the pharmaceutical product ejection nozzle portion is rotated. Then, the first sharp protrusion and the second sharp protrusion penetrated into the capsule are rotated to ensure more air flow to each of the holes drilled in the upper and lower parts of the capsule. , The all-plastic intranasal pharmaceutical product administration device according to any one of claims 1 to 5. The all-plastic intranasal preparation administration device according to any one of claims 1 to 6, wherein the capsule mounting portion is detachably attached to the pressing pump portion. The capsule placement portion, the pharmaceutical product ejection nozzle portion, the first acute-angled protrusion and the second acute-angled protrusion are made of hard plastic, and the pressing pump part is made of soft plastic. 7 The all-plastic intranasal pharmaceutical agent administration device according to any one of the above items. The all-plastic intranasal preparation administration device according to any one of claims 1 to 8, wherein the all-plastic intranasal preparation administration device is disposable. The all-plastic intranasal preparation administration device according to any one of claims 1 to 9, wherein the all-plastic intranasal preparation administration device is transparent and the inside is visible.

Images